Macrophage migration inhibitory factor (MIF) is a pleiotropic cytokine involved in the regulation of inflammation, immune responses, and redox homeostasis. However, its metabolic effects in experimental models remain insufficiently characterized. The aim of the work was to estimate the effect of recombinant MIF on cytokines profile, antioxidant defense markers and LPO indicators at different time points following its single intraperitoneal administration to albino rats. Animals were divided into a control group (n = 20) and three experimental groups (n = 10 each) assessed in 2, 3, and 14 days after MIF administration (10 µg/kg of b.w.), respectively. Serum samples were analyzed for IL-6, IL-10, TNF-α, IL-4, antioxidant markers and LPO products levels by ELISA and standard biochemical assays. It was shown that MIF administration induced time-dependent pro-inflammatory and pro-oxidant effects. Early compensatory anti-inflammatory responses were marked by increased IL-10 and decreased IL-6 levels. However, at the later stages (days 3 and 14), IL-6 and TNF-α elevation, along with IL-4 suppression, indicated a shift toward chronic inflammation. Antioxidant parameters progressively declined, with maximal suppression observed on day 14. Concurrently, a significant accumulation of LPO products confirmed sustained oxidative stress and membrane damage. These findings underscore the potential of MIF as a pharmacological target for the treatment of chronic inflammatory and metabolic disorders.
No takes yet. Share an insight, caveat, or question.
Guliyeva et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: